Cost of Immunotherapy for GI Cancers in India — And the Test You Pay For First

Most people in India with a GI cancer are not candidates for immunotherapy. In colorectal cancer, only tumours reported as MSI-High or mismatch-repair deficient qualify — roughly one in twenty of the cancers that have already spread. Liver, anal, biliary, stomach and oesophageal cancers each have a separate gate. Cost matters only after that gate.

• Colorectal cancer is decided by one lab result — MSI-High or mismatch-repair deficient (dMMR) disease qualifies. That is roughly 15 in 100 colorectal cancers overall, and only about 4 to 5 in 100 of those that have spread (NCCN and ESMO guidance).
• MSS colorectal cancer does not qualify — microsatellite stable tumours, the large majority, are not treated with checkpoint inhibitors on their own outside a clinical trial. No price is worth paying for a treatment the tumour biology does not support.
• Liver cancer (HCC) works differently — there is no MSI gate. Checkpoint inhibitor combinations are an option in advanced, unresectable disease, and eligibility turns on liver function, the state of the underlying liver disease, and general fitness.
• Anal, biliary and upper GI cancers each have their own rule — anal squamous cancer, gallbladder and bile-duct cancer, stomach and oesophageal cancer are separate diseases with separate evidence. A PD-L1 score is often the deciding test in the upper GI group.
• Early-stage disease is usually not the setting — for a GI cancer that can be removed by surgery, surgery with chemotherapy where indicated remains the plan. Immunotherapy before surgery for dMMR rectal cancer is an active research area, discussed case by case, not routine practice.
• Fitness and immune history can rule it out — an active autoimmune condition, ongoing high-dose steroids, an organ transplant or poor performance status can make a checkpoint inhibitor unsafe regardless of the tumour test result.

Testing comes before treatment, and you pay for it first. As of August 2026, mismatch-repair immunohistochemistry runs roughly ₹4,000 to ₹8,000 and MSI testing by PCR roughly ₹6,000 to ₹12,000, both one-time and both run on tissue you have already given. That one result decides whether a lakh-per-cycle conversation is relevant at all.

All figures are indicative only, as of August 2026, and vary by laboratory and city. Mismatch-repair immunohistochemistry usually reports in about a week; a sequencing panel commonly takes two to three weeks. Build that waiting time into the plan rather than discovering it after a cycle has been booked. What these tests cost across Indian laboratories is set out in more detail on biomarker testing cost in India.

A cycle is priced by the drug, not by the cancer. As of August 2026, one cycle of a checkpoint inhibitor runs roughly ₹50,000 to ₹1,50,000 for a domestic or biosimilar product, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Day care and pre-cycle blood tests add a little more.

All figures are indicative only, as of August 2026, and are quoted by product class rather than by brand. The real number depends on the product selected, whether the dose is flat or calculated by body weight, the cycle interval, and the centre. Immunotherapy is given as day care at CION centres, so a routine cycle carries no inpatient bed charge. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION.

Assistance exists, but none of it is automatic. Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS and ESI work to fixed package ceilings that high-cost immunotherapy often sits above. Private insurance usually pays for day-care infusion, subject to sub-limits and pre-authorisation. Choosing a domestic product cuts the drug cost most.

• Aarogyasri (Telangana and Andhra Pradesh) — GI surgery, radiation and chemotherapy packages are well established. High-cost immunotherapy sits in a different bracket, so ask the hospital scheme desk for the current ceiling in writing.
• Ayushman Bharat PM-JAY — the same package-ceiling logic applies nationally. What the scheme does and does not reach is set out on Ayushman Bharat and immunotherapy coverage.
• CGHS, ECHS and ESI — these run on approved rate lists plus prior approval. Approval often takes longer than the gap between two cycles, so start the paperwork before treatment begins.
• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive.
• Manufacturer assistance programmes — several manufacturers run patient-assistance or dose-support programmes in India. Eligibility varies, documentation takes time, and applications usually have to be made before cycle one.
• Domestic and biosimilar products — usually the single largest reduction available. This is a clinical conversation with your oncologist, not a decision to make alone. See how biosimilars change the cost.
• Section 80DDB tax deduction — a deduction is available for specified illnesses including cancer, against a prescribed certificate. Details are on tax relief on immunotherapy costs.

A day-care cycle bill covers the drug, chair and nursing time, the IV set, pre-medication, the oncologist review and observation. Everything else is billed separately — the one-time biomarker tests, response-assessment scans, treatment of any immune-related side effect, and the travel that a cycle every few weeks demands.

There is also no fixed full-course price, because the length is not decided in advance. Treatment continues until the cancer progresses, until a side effect makes it unsafe to continue, or up to a planned ceiling of about two years in many protocols. Plan against three-month and six-month totals first, and revisit the number at every response scan rather than committing to a two-year figure on day one.

The MSI-High and mismatch-repair gate is not unique to the bowel. The same laboratory result decides eligibility in uterine cancer, and a different tissue score does the same job in cervical and breast cancer. These pages show how the gate works elsewhere, and how the treatment pathway itself is run.

• Immunotherapy for Endometrial and Uterine Cancer — the other cancer where mismatch-repair status is the deciding test, and the closest parallel to the colorectal rule described above.
• Immunotherapy for Cervical Cancer — here a PD-L1 score on tumour tissue does the gatekeeping instead, and the testing cost again lands before the treatment cost.
• Immunotherapy Before Surgery for Triple-Negative Breast Cancer — what it looks like when immunotherapy is given before an operation rather than after everything else has been tried.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, side-effect monitoring and cost counselling run as one pathway.

For the colorectal question specifically, immunotherapy for colorectal cancer and the MSI rule covers the eligibility side in depth, and immunotherapy for liver cancer covers the separate liver pathway referred to above.

Decisions for Healing, Not Billing

Cost is discussed openly at the first consultation — including the option of not starting immunotherapy at all if the report or the numbers do not support it.